China Universal Asset Management Co. Ltd. Boosts Position in Dynavax Technologies Co. (NASDAQ:DVAX)

China Universal Asset Management Co. Ltd. increased its holdings in Dynavax Technologies Co. (NASDAQ:DVAX) by 10.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 27,873 shares of the biopharmaceutical company’s stock after acquiring an additional 2,669 shares during the quarter. China Universal Asset Management Co. Ltd.’s holdings in Dynavax Technologies were worth $356,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. GAMMA Investing LLC lifted its position in shares of Dynavax Technologies by 175.5% in the 3rd quarter. GAMMA Investing LLC now owns 2,645 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 1,685 shares during the period. US Bancorp DE lifted its holdings in Dynavax Technologies by 291.4% in the third quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 2,034 shares during the period. Capital Performance Advisors LLP bought a new stake in Dynavax Technologies during the 3rd quarter valued at approximately $45,000. Nisa Investment Advisors LLC grew its holdings in shares of Dynavax Technologies by 44.6% during the 3rd quarter. Nisa Investment Advisors LLC now owns 5,441 shares of the biopharmaceutical company’s stock worth $61,000 after acquiring an additional 1,679 shares during the period. Finally, Wilmington Savings Fund Society FSB purchased a new position in shares of Dynavax Technologies in the 3rd quarter valued at approximately $89,000. Institutional investors own 96.96% of the company’s stock.

Analysts Set New Price Targets

DVAX has been the subject of a number of research reports. HC Wainwright increased their price objective on Dynavax Technologies from $29.00 to $31.00 and gave the stock a “buy” rating in a report on Tuesday, January 14th. StockNews.com raised shares of Dynavax Technologies from a “hold” rating to a “buy” rating in a research report on Tuesday, January 14th.

Dynavax Technologies Stock Up 0.3 %

Shares of NASDAQ:DVAX opened at $13.05 on Monday. The company has a current ratio of 13.23, a quick ratio of 12.34 and a debt-to-equity ratio of 0.33. The stock has a fifty day simple moving average of $12.78 and a two-hundred day simple moving average of $11.82. Dynavax Technologies Co. has a 12-month low of $9.74 and a 12-month high of $13.89. The stock has a market capitalization of $1.72 billion, a price-to-earnings ratio of 100.39 and a beta of 1.34.

Dynavax Technologies (NASDAQ:DVAX) last announced its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported $0.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.10 by $0.02. The company had revenue of $80.63 million for the quarter, compared to analysts’ expectations of $83.64 million. Dynavax Technologies had a net margin of 7.85% and a return on equity of 3.19%. During the same quarter in the previous year, the business posted $0.10 EPS. On average, research analysts anticipate that Dynavax Technologies Co. will post 0.2 earnings per share for the current fiscal year.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.